BR112022000417A2 - Proteínas de toxina de fusão para tratamento de doenças relacionadas a infecções por cmv - Google Patents
Proteínas de toxina de fusão para tratamento de doenças relacionadas a infecções por cmvInfo
- Publication number
- BR112022000417A2 BR112022000417A2 BR112022000417A BR112022000417A BR112022000417A2 BR 112022000417 A2 BR112022000417 A2 BR 112022000417A2 BR 112022000417 A BR112022000417 A BR 112022000417A BR 112022000417 A BR112022000417 A BR 112022000417A BR 112022000417 A2 BR112022000417 A2 BR 112022000417A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- diseases related
- toxin proteins
- fusion toxin
- cmv infections
- Prior art date
Links
- 206010011831 Cytomegalovirus infection Diseases 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000004927 fusion Effects 0.000 title abstract 2
- 108700012359 toxins Proteins 0.000 title abstract 2
- 239000002596 immunotoxin Substances 0.000 abstract 4
- 231100000608 immunotoxin Toxicity 0.000 abstract 4
- 229940051026 immunotoxin Drugs 0.000 abstract 4
- 230000002637 immunotoxin Effects 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19186000 | 2019-07-12 | ||
| PCT/EP2020/067785 WO2021008840A1 (en) | 2019-07-12 | 2020-06-25 | Fusion toxin proteins for treatment of diseases related to cmv infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022000417A2 true BR112022000417A2 (pt) | 2022-03-03 |
Family
ID=67437717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022000417A BR112022000417A2 (pt) | 2019-07-12 | 2020-06-25 | Proteínas de toxina de fusão para tratamento de doenças relacionadas a infecções por cmv |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220281933A1 (https=) |
| EP (1) | EP3997107A1 (https=) |
| JP (1) | JP2022540877A (https=) |
| KR (1) | KR20220032610A (https=) |
| CN (1) | CN114206944A (https=) |
| AU (1) | AU2020312560A1 (https=) |
| BR (1) | BR112022000417A2 (https=) |
| CA (1) | CA3146798A1 (https=) |
| MX (1) | MX2022000433A (https=) |
| WO (1) | WO2021008840A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2603166A (en) * | 2021-01-29 | 2022-08-03 | Thelper As | Therapeutic and Diagnostic Agents and Uses Thereof |
| EP4301394A1 (en) * | 2021-03-03 | 2024-01-10 | Synklino ApS | Compositions for ex vivo organ care |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002018954A2 (en) * | 2000-08-30 | 2002-03-07 | Chemocentryx, Inc. | Inhibition of cmv infection and dissemination |
| CA2437201C (en) * | 2001-02-02 | 2008-11-18 | Chemocentryx, Inc. | Methods and compositions useful for stimulating an immune response |
| EP2038302B1 (en) * | 2006-07-03 | 2012-10-24 | INAGEN ApS | Immunotoxins for the treatment of diseases related to cmv infection |
| WO2010070394A1 (en) * | 2008-12-17 | 2010-06-24 | Universite Pierre Et Marie Curie-Paris Vi | Modulators of the cx3cr1 receptor and therapeutic uses thereof |
| TWI570240B (zh) * | 2011-09-09 | 2017-02-11 | 默沙東公司 | 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ |
| EP3262063B1 (en) * | 2015-02-26 | 2021-09-22 | Var2 Pharmaceuticals ApS | Immunotherapeutic targeting of placental-like chondroitin sulfate using chimeric antigen receptors (cars) and immunotherapeutic targeting of cancer using cars with split-protein binding systems |
| US10849960B2 (en) * | 2017-09-08 | 2020-12-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer |
-
2020
- 2020-06-25 CN CN202080050524.5A patent/CN114206944A/zh active Pending
- 2020-06-25 WO PCT/EP2020/067785 patent/WO2021008840A1/en not_active Ceased
- 2020-06-25 KR KR1020227004798A patent/KR20220032610A/ko not_active Ceased
- 2020-06-25 BR BR112022000417A patent/BR112022000417A2/pt unknown
- 2020-06-25 JP JP2022502075A patent/JP2022540877A/ja active Pending
- 2020-06-25 AU AU2020312560A patent/AU2020312560A1/en not_active Abandoned
- 2020-06-25 EP EP20734206.4A patent/EP3997107A1/en not_active Withdrawn
- 2020-06-25 CA CA3146798A patent/CA3146798A1/en active Pending
- 2020-06-25 US US17/626,675 patent/US20220281933A1/en not_active Abandoned
- 2020-06-25 MX MX2022000433A patent/MX2022000433A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022000433A (es) | 2022-04-25 |
| US20220281933A1 (en) | 2022-09-08 |
| EP3997107A1 (en) | 2022-05-18 |
| CN114206944A (zh) | 2022-03-18 |
| CA3146798A1 (en) | 2021-01-21 |
| WO2021008840A1 (en) | 2021-01-21 |
| AU2020312560A1 (en) | 2022-03-03 |
| JP2022540877A (ja) | 2022-09-20 |
| KR20220032610A (ko) | 2022-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019009255A (es) | Proteínas quiméricas dirigidas y sus usos. | |
| BR112021012222A8 (pt) | Molécula de ligação direcionada à célula melhorada | |
| BR112022010574A2 (pt) | Composições farmacêuticas compreendendo cabotegravir | |
| BR112019016497A2 (pt) | 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de câncer. | |
| JOP20170135A1 (ar) | مركبات ديازاسبيروألكيل مثيل-إندول | |
| MX389697B (es) | Nuevos derivados de pirazolopirimidina. | |
| BR112016030541A2 (pt) | métodos para o tratamento de infecções fúngicas | |
| SA523440384B1 (ar) | مركبات الفوسفوليبيدات واستخداماتها | |
| BR112023002951A2 (pt) | Compostos de fosfolipídio e usos destes | |
| MX2024005705A (es) | Composiciones de liquidos ionicos. | |
| BR112019018615A2 (pt) | compostos antimicrobianos, composições e usos dos mesmos | |
| MX2023009921A (es) | Formulaciones de proteinas de fusion ace2-fc. | |
| MX2020008454A (es) | Composicion inmunogenica que comprende antigenos estafilococicos. | |
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
| EA202290048A1 (ru) | Лекарственное средство и его применение для лечения бактериальных инфекций, связанных с биопленкой | |
| BRPI0916885B8 (pt) | composição farmacêutica | |
| BR112022000417A2 (pt) | Proteínas de toxina de fusão para tratamento de doenças relacionadas a infecções por cmv | |
| WO2020198662A8 (en) | Clec9a-based chimeric protein complexes | |
| BR112021024845A2 (pt) | Combinação para o tratamento de infecções causadas por mycoplasma genitalium | |
| BR112022006734A2 (pt) | Moduladores atf6 e usos dos mesmos | |
| JOP20250174A1 (ar) | بروتينات اندماج il-12 fc | |
| BR112021014911A2 (pt) | Belantamabe mafodotina em combinação com pembrolizumabe para tratamento de câncer | |
| EP3802573A4 (en) | VACCINE COMPOSITION WITH RECOMBINANT PROTEIN OF ATTENTIONED ENTEROTOXIN AND CYTOTOXIN FROM STAPHYLOCOCCUS AUREUS | |
| EP4285910A4 (en) | Pharmaceutical composition for treatment of neuroinflammation, comprising eleutheroside b as active ingredient | |
| WO2021081110A3 (en) | Peptides and use thereof |